BRAF and melanoma: For this purpose, we selected a homogeneous group of 7 stage IIIC melanoma patients with BRAF wild-type status and locoregional metastases located exclusively to the pelvic region, all of whom were un-eligible for novel immunotherapy and were treated with melphalan HPP, in accordance with percentage MGMT promoter methylation levels in tissue-specimen, as a relevant index of melphalan efficacy [14].